Evaluation of hybrid PET/CT imaging with the 68Ga-labelled PSMA ligand in patients with prostate cancer and biochemical progression in the low-range values of PSA after radical prostatectomy-Reference-Cited by-同舟云学术

Evaluation of hybrid PET/CT imaging with the 68Ga-labelled PSMA ligand in patients with prostate cancer and biochemical progression in the low-range values of PSA after radical prostatectomy

Published:2022-01-18 Issue:1 Volume:54 Page:29
ISSN:1314-6408
Container-title:Scripta Scientifica Medica
language:
Short-container-title:SSM

Author:

Dyankova Marina,Dancheva Zhivka,Dokova Klara,Klisarova Aneliya

Publisher

Medical University Prof. Dr. Paraskev Stoyanov - Varna

Subject

General Medicine

Reference32 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi: 10.3322/caac.21590.

2. Zacho HD, Nielsen JB, Dettmann K, Haberkorn U, Langkilde NC, Jensen JB, Petersen LJ. 68Ga-PSMA PET/CT in patients with biochemical recurrence of prostate cancer: a prospective, 2-center study. Clin Nucl Med. 2018;43(8):579-85. doi: 10.1097/RLU.0000000000002169.

3. Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2017;58(6):947-52. doi: 10.2967/jnumed.116.185538.

4. Bashir U, Tree A, Mayer E, Levine D, Parker C, Dearnaley D, et al. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46(4):901-7. doi: 10.1007/s00259-018-4249-z.

5. Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, Briganti A, et al. Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(1):136-46. doi: 10.1007/s00259-019-04505-2.